# Clinical Trial Landscape: 04_colorectal_kras_g12c

*Generated: 2026-01-05 18:29:13*

## Summary

- **Total Trials**: 100
- **Flagged for Review**: 0
- **Search Terms Used**: 12

## Phase Distribution

| Phase | Count | Distribution |
|-------|-------|--------------|
| Phase 1 | 31 | ██████ 31.0% |
| Phase 2 | 17 | ███ 17.0% |
| Phase 1/Phase 2 | 15 | ███ 15.0% |
| Phase 3 | 12 | ██ 12.0% |
| Not Applicable | 12 | ██ 12.0% |
| Unknown | 10 | ██ 10.0% |
| Phase 2/Phase 3 | 2 |  2.0% |
| Early Phase 1 | 1 |  1.0% |

## Status Distribution

- **Recruiting**: 90 (90.0%)
- **Not yet recruiting**: 5 (5.0%)
- **Enrolling by invitation**: 5 (5.0%)

## Top Sponsors

| Sponsor | Trial Count |
|---------|-------------|
| National Cancer Institute (NCI) | 8 |
| M.D. Anderson Cancer Center | 5 |
| Memorial Sloan Kettering Cancer Center | 5 |
| Merck Sharp & Dohme LLC | 5 |
| City of Hope Medical Center | 5 |
| Hoffmann-La Roche | 4 |
| Mirati Therapeutics Inc. | 4 |
| Eli Lilly and Company | 4 |
| Amgen | 3 |
| Revolution Medicines, Inc. | 3 |
| Bristol-Myers Squibb | 3 |
| Dana-Farber Cancer Institute | 2 |
| TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Thera | 2 |
| University of Nebraska | 1 |
| Vaccinogen Inc | 1 |

## Interventions

| Intervention | Occurrences |
|--------------|-------------|
| Pembrolizumab | 20 |
| Cisplatin | 12 |
| Cetuximab | 12 |
| Pemetrexed | 12 |
| Carboplatin | 12 |
| Adagrasib | 11 |
| Sotorasib | 9 |
| Bevacizumab | 7 |
| Biospecimen Collection | 7 |
| Placebo | 6 |
| Oxaliplatin | 6 |
| Divarasib | 5 |
| MK-1084 | 5 |
| Computed Tomography | 4 |
| Magnetic Resonance Imaging | 4 |
| Gemcitabine | 4 |
| Leucovorin | 3 |
| Entrectinib | 3 |
| Atezolizumab | 3 |
| FOLFIRI | 3 |

## Geographic Distribution

| Country | Trial Count |
|---------|-------------|
| United States | 100 |
| Spain | 33 |
| Australia | 28 |
| South Korea | 25 |
| France | 25 |
| Italy | 25 |
| Japan | 22 |
| Taiwan | 21 |
| Canada | 21 |
| Netherlands | 20 |
| Germany | 20 |
| Poland | 19 |
| China | 17 |
| Belgium | 16 |
| Brazil | 16 |

## Search Term Provenance

| Term | Source | Confidence |
|------|--------|------------|
| KRAS G12C | manual | 1.0 |
| KRASG12C | manual | 0.9 |
| KRAS-G12C | manual | 0.9 |
| colorectal cancer | manual | 1.0 |
| KRAS G12C colorectal cancer | manual | 1.0 |
| KRAS G12C metastatic colorectal cancer | llm | 0.9 |
| KRAS G12C adenocarcinoma | llm | 0.9 |
| colon cancer | llm | 0.8 |
| colorectal adenocarcinoma | llm | 0.8 |
| KRAS p.G12C | llm | 0.9 |
| KRASp.G12C | llm | 0.8 |
| KRAS-p.G12C | llm | 0.8 |

## All Trials

| NCT ID | Phase | Status | Sponsor | Title |
|--------|-------|--------|---------|-------|
| [NCT07288034](https://clinicaltrials.gov/study/NCT07288034) | Phase 2 | Not yet recruiting | City of Hope Medical... | Immunotherapy Biomarker Collection ... |
| [NCT02448173](https://clinicaltrials.gov/study/NCT02448173) | Phase 3 | Not yet recruiting | Vaccinogen Inc | A Randomized Multicenter Study of A... |
| [NCT07221357](https://clinicaltrials.gov/study/NCT07221357) | Phase 2/Phase 3 | Recruiting | Bristol-Myers Squibb | ROSETTA CRC-203: A Blinded, Randomi... |
| [NCT07225309](https://clinicaltrials.gov/study/NCT07225309) | Not Applicable | Not yet recruiting | Memorial Sloan Kette... | Trial of Meaning Centered Psychothe... |
| [NCT07227025](https://clinicaltrials.gov/study/NCT07227025) | Phase 1/Phase 2 | Recruiting | Janssen Research & D... | A Phase 1/2 Study Evaluating the Sa... |
| [NCT06822530](https://clinicaltrials.gov/study/NCT06822530) | Not Applicable | Enrolling by invitation | Fred Hutchinson Canc... | PROACT: Promoting Follow-Up of Abno... |
| [NCT07115875](https://clinicaltrials.gov/study/NCT07115875) | Not Applicable | Not yet recruiting | University of Oklaho... | Improving Rates of Diagnostic Colon... |
| [NCT07262619](https://clinicaltrials.gov/study/NCT07262619) | Phase 1/Phase 2 | Not yet recruiting | Eikon Therapeutics | A Multicenter, Multi-Part, Phase 1/... |
| [NCT07209111](https://clinicaltrials.gov/study/NCT07209111) | Phase 2 | Recruiting | Merck Sharp & Dohme ... | A Phase 2, Open-Label, Multicenter,... |
| [NCT07223047](https://clinicaltrials.gov/study/NCT07223047) | Phase 1/Phase 2 | Recruiting | Bristol-Myers Squibb | A Phase 1/2a, Open-Label, Multicent... |
| [NCT07217171](https://clinicaltrials.gov/study/NCT07217171) | Phase 1 | Recruiting | EvolveImmune United,... | A Phase 1 Dose-Escalation and Expan... |
| [NCT07223424](https://clinicaltrials.gov/study/NCT07223424) | Phase 2 | Recruiting | Diwakar Davar | Patient Preference for Subcutaneous... |
| [NCT06793215](https://clinicaltrials.gov/study/NCT06793215) | Phase 3 | Recruiting | Hoffmann-La Roche | A Phase III, Randomized, Open-Label... |
| [NCT07221058](https://clinicaltrials.gov/study/NCT07221058) | Phase 1 | Recruiting | Fox Chase Cancer Cen... | Adaptive Radiation BOost for Rectal... |
| [NCT07190248](https://clinicaltrials.gov/study/NCT07190248) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | A Phase 3, Randomized, Open-label, ... |
| [NCT07141706](https://clinicaltrials.gov/study/NCT07141706) | Phase 1 | Recruiting | DualityBio Inc. | A Phase 1a/1b, Multicenter, Open-La... |
| [NCT06883838](https://clinicaltrials.gov/study/NCT06883838) | Not Applicable | Enrolling by invitation | The University of Te... | Enhancing Primary Care Capacity for... |
| [NCT06910657](https://clinicaltrials.gov/study/NCT06910657) | Phase 1 | Recruiting | ViroMissile, Inc. | A First-in-human, Phase I, Multi-ce... |
| [NCT07094204](https://clinicaltrials.gov/study/NCT07094204) | Phase 1 | Recruiting | Astellas Pharma Inc | A Phase 1 Study of ASP5834 in Parti... |
| [NCT06997497](https://clinicaltrials.gov/study/NCT06997497) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | A Phase 3, Randomized, Open-label, ... |
| [NCT06371768](https://clinicaltrials.gov/study/NCT06371768) | Not Applicable | Recruiting | Duke University | Symptom Management and Transitionin... |
| [NCT06880055](https://clinicaltrials.gov/study/NCT06880055) | N/A | Recruiting | Guardant Health, Inc... | Shield Post-Approval Study Protocol |
| [NCT06995898](https://clinicaltrials.gov/study/NCT06995898) | Not Applicable | Recruiting | National Cancer Inst... | The Vanguard Study: Testing a New W... |
| [NCT07046585](https://clinicaltrials.gov/study/NCT07046585) | N/A | Recruiting | Natera, Inc. | Evaluation of the Natera Colorectal... |
| [NCT07023731](https://clinicaltrials.gov/study/NCT07023731) | Phase 1/Phase 2 | Recruiting | Arvinas Inc. | A Phase 1/2 Clinical Trial to Evalu... |
| [NCT06881784](https://clinicaltrials.gov/study/NCT06881784) | Phase 3 | Recruiting | Revolution Medicines... | RASolve 301: Phase 3 Multicenter, O... |
| [NCT06875310](https://clinicaltrials.gov/study/NCT06875310) | Phase 3 | Recruiting | Mirati Therapeutics ... | A Randomized, Double-Blind, Phase 3... |
| [NCT06917079](https://clinicaltrials.gov/study/NCT06917079) | Phase 1 | Recruiting | TheRas, Inc., d/b/a ... | A Phase 1a/1b Open-Label Study Eval... |
| [NCT06890598](https://clinicaltrials.gov/study/NCT06890598) | Phase 3 | Recruiting | Eli Lilly and Compan... | A Phase 3, Multicenter, Double-Blin... |
| [NCT06804824](https://clinicaltrials.gov/study/NCT06804824) | Phase 1 | Recruiting | Vividion Therapeutic... | A Phase 1/1b, Open-Label, Multicent... |
| [NCT06730750](https://clinicaltrials.gov/study/NCT06730750) | Phase 1/Phase 2 | Recruiting | Bristol-Myers Squibb | A Phase 1/2a, Multicenter, Open-lab... |
| [NCT06720987](https://clinicaltrials.gov/study/NCT06720987) | Phase 1 | Recruiting | Kumquat Biosciences ... | A Phase 1/1b, Open-label, Multicent... |
| [NCT06634875](https://clinicaltrials.gov/study/NCT06634875) | Phase 2 | Recruiting | Buzzard Pharmaceutic... | A Phase IIa, Non-Randomized, Open-L... |
| [NCT06807619](https://clinicaltrials.gov/study/NCT06807619) | Phase 1 | Recruiting | Memorial Sloan Kette... | BrainMet ADePPT (Anticancer Drug Pe... |
| [NCT06607185](https://clinicaltrials.gov/study/NCT06607185) | Phase 1 | Recruiting | Eli Lilly and Compan... | A Phase 1a/1b Study of the Pan-KRAS... |
| [NCT06562192](https://clinicaltrials.gov/study/NCT06562192) | Phase 1 | Recruiting | Novartis Pharmaceuti... | Phase I Open-label, Multi-center St... |
| [NCT06333951](https://clinicaltrials.gov/study/NCT06333951) | Phase 1 | Recruiting | Amgen | A Phase 1b Study Evaluating the Saf... |
| [NCT06462521](https://clinicaltrials.gov/study/NCT06462521) | Not Applicable | Enrolling by invitation | Indiana University | Cold Snare Piecemeal Resection vs C... |
| [NCT06582771](https://clinicaltrials.gov/study/NCT06582771) | Phase 2 | Recruiting | Memorial Sloan Kette... | A Phase 2 Study of First-line Sotor... |
| [NCT06412198](https://clinicaltrials.gov/study/NCT06412198) | Phase 1/Phase 2 | Recruiting | M.D. Anderson Cancer... | A Multicenter Phase 1b/2 Study of A... |
| [NCT06248606](https://clinicaltrials.gov/study/NCT06248606) | Phase 2 | Recruiting | Ryan Gentzler, MD | Phase II Study of Adagrasib + Stere... |
| [NCT05638295](https://clinicaltrials.gov/study/NCT05638295) | Phase 2 | Recruiting | National Cancer Inst... | A Randomized Phase II Study of AMG ... |
| [NCT06252649](https://clinicaltrials.gov/study/NCT06252649) | Phase 3 | Recruiting | Amgen | Phase 3 Multicenter, Randomized, Op... |
| [NCT06447662](https://clinicaltrials.gov/study/NCT06447662) | Phase 1 | Recruiting | Pfizer | A Phase 1 Open-Label Study of PF-07... |
| [NCT06345729](https://clinicaltrials.gov/study/NCT06345729) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | A Phase 3, Randomized, Double-blind... |
| [NCT06343402](https://clinicaltrials.gov/study/NCT06343402) | Phase 1 | Recruiting | TheRas, Inc., d/b/a ... | A Phase 1a/1b Open-Label Study Eval... |
| [NCT05961709](https://clinicaltrials.gov/study/NCT05961709) | Phase 2 | Recruiting | M.D. Anderson Cancer... | The Phoenix Trial: Phase II Trial o... |
| [NCT06746012](https://clinicaltrials.gov/study/NCT06746012) | Not Applicable | Recruiting | Ohio State Universit... | Designing a Dyad-Based MHealth Inte... |
| [NCT06249282](https://clinicaltrials.gov/study/NCT06249282) | Phase 1 | Recruiting | City of Hope Medical... | A Phase I Clinical Trial of Carfilz... |
| [NCT06149481](https://clinicaltrials.gov/study/NCT06149481) | Phase 1/Phase 2 | Recruiting | National Cancer Inst... | Phase I/II Study of the Combination... |

*... and 50 more trials (see trials.csv for full list)*
